Last reviewed · How we verify

Part B: Expansion Cohort of Cantrixil

Kazia Therapeutics Limited · Phase 1 active Small molecule

Part B: Expansion Cohort of Cantrixil is a Small molecule drug developed by Kazia Therapeutics Limited. It is currently in Phase 1 development. Also known as: TRX-E-002-1 in 20% SBECD.

At a glance

Generic namePart B: Expansion Cohort of Cantrixil
Also known asTRX-E-002-1 in 20% SBECD
SponsorKazia Therapeutics Limited
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Part B: Expansion Cohort of Cantrixil

What is Part B: Expansion Cohort of Cantrixil?

Part B: Expansion Cohort of Cantrixil is a Small molecule drug developed by Kazia Therapeutics Limited.

Who makes Part B: Expansion Cohort of Cantrixil?

Part B: Expansion Cohort of Cantrixil is developed by Kazia Therapeutics Limited (see full Kazia Therapeutics Limited pipeline at /company/kazia-therapeutics-limited).

Is Part B: Expansion Cohort of Cantrixil also known as anything else?

Part B: Expansion Cohort of Cantrixil is also known as TRX-E-002-1 in 20% SBECD.

What development phase is Part B: Expansion Cohort of Cantrixil in?

Part B: Expansion Cohort of Cantrixil is in Phase 1.

Related